Clinical Trial Detail

NCT ID NCT02767804
Title eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Xcovery Holding Company, LLC
Indications

lung non-small cell carcinoma

Therapies

Crizotinib

Ensartinib

Age Groups: adult

Additional content available in CKB BOOST